Barclays Maintains Underweight on Zimmer Biomet Holdings, Lowers Price Target to $125
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Matt Miksic maintains an Underweight rating on Zimmer Biomet Holdings (NYSE:ZBH) and lowers the price target from $130 to $125.
May 31, 2024 | 6:16 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Barclays analyst Matt Miksic maintains an Underweight rating on Zimmer Biomet Holdings and lowers the price target from $130 to $125.
The Underweight rating and lowered price target from $130 to $125 by Barclays suggest a bearish outlook on Zimmer Biomet Holdings. This is likely to negatively impact the stock price in the short term as investors react to the downgraded expectations.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100